Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC gets funding to develop organ-on-a-chip facility
The facility will reduce the amount of animals needed for in-vitro testing.

It will be the first organ-on-a-chip facility created for veterinary species.

The Royal Veterinary College (RVC) researchers have been awarded a grant which will allow them to develop the first ever organ-on-a-chip facility for veterinary species, reducing the amount of animals needed for in-vitro testing.

Organs-on-chips (OoC) are systems that contain engineered or natural miniature tissues grown inside microfluidic chips.

They are developed to mimic species physiology better than traditional 2D cell culturing, controlling cell microenvironments and maintaining structures and functions of tissues and organs, such as the blood-brain barrier, lungs and heart, while being constantly supplied with necessary nutrients.

The technology will reflect animal tissue structures to predict responses to a wide range of stimuli, including vaccines, pathogens, environmental conditions and cell-to-cell interactions.

This will help bridge the gap between animal and human systems, allowing for drug and vaccine testing and studies into how cells interact with each other and pathogens without the use of live animal testing.

The RVC’s OoC project has been funded by UK Research and Innovation to assess the development of new vaccines and vaccine approaches by better understanding host-pathogen interactions

This will also develop regenerative medicine therapies such as stem cell therapy for tendon, heart and eye conditions, kidney failure and cancers in multi-cell systems.

The research will be led by RVC’s newly created Centre for Vaccinology and Regenerative Medicine.

Dirk Werling, professor of molecular immunology at the RVC, said: “The organ-on-a-chip is one of the top 10 emerging technologies and we are very proud to be able to establish this technology at the RVC, thus actively contributing to the development of new treatment strategies as well as further reducing the usage of animals for in-vivo testing and therefore contributing to the 3Rs – replacement, reduction and refinement.”

Image (C) RVC

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.